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Abstract 
Oral neoplasm constitutes a predominant class of cancer that is encountered in South India. This is in large part due to the elevated risk 
of oncogenesis as a result of the habit of chewing of quids containing betel leaves, areca nut and smokeless tobacco. An array of 
molecular events are induced during the transformation of the buccal epithelium, among them the over-expression of oncogene products 
plays a key role. The c-Myc protein, a regulator of a number of key cellular signalling pathways, plays a pivotal role in a number of 
malignancies. The present study was undertaken to evaluate expression of the c-Myc protein in tumours of the oral cavity from the South 
Indian population, predominantly oral squamous cell carcinoma (OSCC). The c-Myc protein was over-expressed in 80% of the cases 
studied. Taking into account the pivotal role demonstrated for c-Myc in tumourigenesis, our observations suggest a key role for Myc 
oncoprotein in the genesis of OSCC as well as its potential as a therapeutic target in this population. 
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Introduction
In Southern India, of the various classes of malignancies 
presenting at the clinic, a large proportion are cancers of the 
oral cavity. Oral malignancies in this population are unique as 
these are generated by biological alterations due to insult by 
physical and chemical agents due to the use of quids for 
extended periods of time [1,2]. In experimental models, the 
ingredients from the quids have demonstrated induction of 
cellular and molecular changes, including the generation of 
reactive oxygen species (ROS) and DNA damage in the 
hamster pouch model [3,4]. In a study conducted on 140 
patients, with age- and sex-matched controls, with oral cancers 
from Central India, tobacco use, smoking and alcohol 
consumption emerged as contributing factors that act in a 
synergistic fashion in the induction of oral neoplasia [5]. 
Furthermore, multi-step oral epithelial carcinogenesis models 
induced in the laboratory employing systematic genetic 
alterations clearly indicated that in addition to changes in cyclin 
D1 and p53, c-Myc expression along with the acquisition of 
telomerase activity was pivotal for neoplastic transformation of 
these tumours [6]. 
Even though the contribution of quid chewing to elevating the 
oral cancer risk is undisputed, the diversity in the use of the 
various combinations of areca, betel leaves and tobacco in 
various countries as well as in the various regions in India [1] 
warrants comprehensive molecular characterization of the oral 
cancers from this region. A number of studies by cancer 
researchers with respect to molecular mechanisms underlying 
oncogenesis have shown the emergence of c-Myc expression 
as a key event (for reviews: [7–9]). Detailed studies have shown 
that this is in part due to the seminal role the Myc oncoprotein 
plays in a number of cellular signalling pathways. 
Transcriptional regulation of the telomerase, a key molecule in 
solid tumours [10] as well as leukaemias [11], is shown to be 
mediated by the Ets transcription factor family with the 
involvement of c-Myc [12]. Similarly, the WNT1 signalling 
pathway also targets c-Myc during tumour progression [13], 
whereas the elevated prolyl isomerase, Pin1 increases the 
transcription of c-Myc [14]. Genome-wide profiling of OSCC has 
also shown that, among other genes, gain of c-Myc gene 
occurred at a high frequency [15]. Even though gene 
amplification mainly contributes to elevated c-Myc protein 
levels, alternate modes of regulation mediated via c-Myc 
specific transcription factors can also lead to a similar end point 
[16]. Hence, in the present investigation, c-Myc protein 
identification in oral cancers was made the focus of the study. 
Additionally, therapeutic strategies that target c-Myc hold 
promise in the management of cancers that over-express the 
Myc oncoprotein [17]. 
 
Patients and methods
Patient and tumour sample  
Tumour samples used in the study were from patients 
presenting with tumour of the oral cavity at the Regional Cancer 
Center-Kidwai Memorial Institute of Oncology, Bangalore, India. 
History of the patients included in the study indicated that they 
were all habitual chewers of quid with betel leaves, areca nut 
and tobacco and retained the quid in the mouth for prolonged 
periods of time. The age of the patients ranged from 32 to 80 
years. The SCC were diagnosed and graded using the following 
criteria: grade I, well differentiated; grade II, moderately 
differentiated. The following parameters were used for tumour-
node-metastasis (TNM) staging. For tumour size, T1: 0–2 cm; 
T2: 2–4 cm; T3: > 4 cm; and T4: extensive spread of the 
tumour, or if there is involvement of nerve or bone. N0: no 
clinically palpable cervical lymph nodes or palpable nodes, but 
metastasis suspected. N1: clinically palpable-contra/homo 
lateral nodes that are not fixed, metastasis suspected. N2: 
clinically palpable contra lateral or bilateral cervical lymph nodes 
that are not fixed, metastasis suspected. N3: clinically palpable 
lymph nodes that are fixed, metastasis suspected. M0: No 
distant metastasis; M1: clinical and radiographic evidence of 
metastasis. 
Tissue specimens and immunohistochemistry
Tumour tissue samples were obtained by biopsy as well as by 
surgery. The tissue specimens were fixed in 10% formalin prior 
to embedding in paraffin wax. Sections of the tumour were 
stained with Haematoxylin-Eosin (H&E) and graded for the 
stage of the disease by the pathologists. For immunoreactivity 
studies with c-Myc, 5 µM paraffin sections on glass slides were 
deparaffinized and processed for studies. 
Immunohistochemistry was performed using anti-Myc 
antibodies (Oncor) by standard protocols as described earlier 
[18]. Counterstaining was done with haematoxylin. Sections 
were mounted in glycerin for microscopic analysis. Treatment of 
tissue sections with all the reagents except the anti-Myc 
antibody served as controls. Analyses for the immunoreactivity 
of the antibodies were performed by light microscopy. 
























The majority of the tumours in the cancer patient population 
included in the present study were diagnosed as squamous cell 
carcinoma (Table 1). There was a preponderance of cases in 
the T3/T4 stages of disease. Immunohistochemical analysis 
revealed that 80% of the tumours expressed the c-Myc 
oncoprotein. A case of squamous cell carcinoma of the soft 
palate that was diagnosed as grade I was negative for anti-Myc 
staining. Among the other tumours that were negative were two 
cases of grade II as well as grade III OSCC. Interestingly, an 
epidermoid carcinoma, stage IV did not show elevated 
expression of the c-Myc protein. There were no detectable 
levels of the Myc oncoprotein in the fibrous tissue of a patient 
who presented with inflammation but no malignancy. Dysplastic 
lesions of the tongue displayed positive c-Myc immunoreactivity. 
This was also the case for acanthotic-stratified epithelium. One 
case of verrucous carcinoma, a variant of the SCC, that was 
investigated in the current study showed a moderate level of 
intensity for anti-Myc staining. 
Representative results of immunohistochemistry for anti-Myc 
are depicted in Figure 1. Tissue sections judged as positive 
showed distinct staining in the tumour [Figure 1A and B]. 
Tumour tissue(s) that lacked this was scored as negative for the 
Myc oncoprotein [Figure 1C]. Tissue sections that were 
processed with all the reagents except the anti-Myc antibody 
failed to show any reactivity, confirming the specificity of the 
reaction observed in the positive samples [Figure 1D]. 
 
Discussion
Cancer of the oral cavity is a neoplasia, which occurs with high 
frequency in the South Indian population due to quid chewing 
habits. Even though the habit is largely prevalent in the Indian 
subcontinent, the ingredients of the quid vary from region to 
region [1]. We wanted to determine, within the South Indian 
population, the key tumour markers that are expressed in oral 
carcinoma that could have prognostic as well as diagnostic 
implications. Previously, we have reported the expression of 
carcinoembryonic antigen (CEA) in a number of OSCC from 
patients from this region [18]. In the present study, we focused 
on the expression of the c-Myc protein in the oral cancers. 
Investigations into the progression of pre-neoplastic lesions 
suggest that the c-Myc oncoprotein is expressed in the various 
stages, including benign keratoses [19]. A plethora of molecular 
changes are identified including mutations in ras as well as p53 
and elevated expression of c-Myc [20]. c-Myc over-expression 
is also correlated with poor prognosis of OSCC [21]. Multiple 
gene amplifications, including c-Myc, were observed in head 
and neck SCC [22] and the over-expression of the cyclin-
dependent Kinase 4 (Cdk4) either by gene amplification or 
through the c-Myc regulated pathway may also play a key role 
in the progression of these tumours [23]. 
In an investigation of oral cancers from the Eastern Indian 
population, of all the OSCC cases studied, 56% had anti-Myc 
immunoreactivity [24]. In our studies, c-Myc expression was 
observed in tumours from all stages, suggesting possible 
involvement during the various stages of the neoplastic process. 
This can be visualized especially in light of the fact that c-Myc is 
a regulator of multiple cell signalling pathways including hTERT, 
which is universally activated in various malignancies and is 
critical for maintenance of cellular immortalization. Eversole and 
Sapp [19] also noted c-Myc expression in both pre-cancerous 
(keratoses) and early stage lesions in patients from North 
America. In lip carcinogenesis, c-Myc expression was evident in 
only very late stages of the disease [25]. Hence, there is a 
broad spectrum of c-Myc activation in various head and neck 
cancers from different parts of the world. 
Detection of the c-Myc protein in the majority of the OSCC we 
analysed attests to the seminal role, this molecule plays in the 
neoplastic progression. With an array of signalling pathways 
that can be regulated by c-Myc, it is conceivable that the 
oncoprotein is involved in several cascades of events necessary 
for initiation and maintenance of the neoplastic state at various 
stages. Additionally, recent studies on the management of 
osteosarcoma has unveiled that the c-Myc status may 
contribute to therapeutic response and clinical outcome [26]. 
Elevated expression of this oncogene exhibited unfavourable 
clinical outcome when methotrexate treatment was used. 
Methotrexate is a preferred chemotherapeutic agent in oral 
cancer treatment and if the aforementioned scenario also 
applies for OSCC, appropriate clinical strategies need to be 
designed based on the presence/absence of the c-Myc 
oncoprotein in oral cancer. Furthermore, tumours that over-
express the Myc protein should be amenable to therapeutic 
modalities such as anti-sense and siRNA that specifically target 
c-Myc resulting in efficacious management of oral cancers. 






















Table 1: Patient history, tumour pathology and immunohistochemical staining for Myc in oral cancers
 
 


























Figure 1: Immunohistochemical staining for Myc oncoprotein in oral squamous cell carcinoma. Tumour sections were processed as detailed in 
the Methods section. The sections were examined under light microscopy for positive staining (A and B) and lack of reaction (C). Control 
assays were performed in parallel with the exclusion of the anti-Myc antibody from the reaction (D). 
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